Cargando…

Differential response to anakinra and adalimumab in a patient with DADA2 syndrome

Detalles Bibliográficos
Autores principales:	Toz, B, Erer, B, Kamali, S, Ocal, L, Gul, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599387/ http://dx.doi.org/10.1186/1546-0096-13-S1-P201

Ejemplares similares

How safe it is to treat pregnant FMF patients with Anakinra?
por: Ozdogan, H, et al.
Publicado: (2015)

Early effects of Anakinra in corticosteroid naïve SOJIA patients
por: Wulffraat, NM, et al.
Publicado: (2008)

Anakinra treatment in patients with Familial Mediterranean Fever: a single-center experience
por: Ugurlu, S, et al.
Publicado: (2015)

Anakinra treatment in patients with systemic-onset juvenil idiopathic arthritis: “The Valencia Experience”
por: Marvillet, I, et al.
Publicado: (2011)

Dadá : documentos
Publicado: (1977)

Anakinra for secondary amyloidosis in an adolescent with FMF and Behcet Disease
por: Bilginer, Y, et al.
Publicado: (2008)

Anakinra in systemic juvenile idiopathic arthritis (soJIA) non responsive to antiTNF
por: Pontikaki, I, et al.
Publicado: (2008)

A novel mutation in NLRC4 in a large pedigree with an anakinra responsive autoinflammatory disease
por: Volker-Touw, N, et al.
Publicado: (2015)

Successful kidney transplantation during anakinra treatment without complications
por: Mulders-Manders, C, et al.
Publicado: (2015)

Efficacy of adalimumab in sarcoidosis
por: Kamphuis, LSJ, et al.
Publicado: (2010)

Almanaque Dadá /
Publicado: (1992)

Palabra dada /
por: Lévi-Strauss, Claude
Publicado: (1984)

Teatro Dada /
Publicado: (1971)

Quality of life changes with canakinumab therapy in adults with colchicine resistant FMF
por: Gul, A, et al.
Publicado: (2015)

Anakinra (Kineret) in psoriasis and psoriatic arthritis: a single-center, open-label, pilot study
por: Gibbs, A, et al.
Publicado: (2005)

The effect of Anakinra on Quality-of-Life in a family with colchicine-resistant FMF
por: van der Hilst, J, et al.
Publicado: (2015)

Recurrent poliserositis succesfully treated with IL-1 receptor antagonist Anakinra
por: Lovillo, MS Camacho, et al.
Publicado: (2011)

Complete regression of hip structural damage with anakinra: a case report
por: Aguiar, Francisca, et al.
Publicado: (2014)

Palabras dadas : discursos /
por: Ladrón de Guevara, Sara
Publicado: (2016)

P19 Our experience diagnosing and treating deficiency of adenine deaminase 2 (DADA2) vasculitis
por: Al Daqqaq, Nawal, et al.
Publicado: (2023)

Cronic non-bacterial osteomyelitis (CNO) in a cohort of pediatric patients: clinical, biological and radiological response to treatment with Anakinra
por: Pardeo, M, et al.
Publicado: (2015)

Dadá : historia de una subversión /
por: Béhar, Henri
Publicado: (1996)

Clinical follow-up on a cohort of patients with deficiency of adenosine deaminase 2 (DADA2)
por: Barron, K, et al.
Publicado: (2015)

Evaluation of the JIA treatment with adalimumab in ukraine
por: Ponochevna, Elena, et al.
Publicado: (2014)

Long-term follow-up of systemic onset juvenile idiopathic arthritis patients treated with Anakinra
por: Gattorno, Marco, et al.
Publicado: (2011)

Dada, Surrealism, and their heritage
por: Rubin, William Stanley
Publicado: (1968)

Familial mediterranean fever and pauciimmune renal vasculitis: the role of IL-1 blockade (Anakinra)
por: Lovillo, MS Camacho, et al.
Publicado: (2011)

PReS-FINAL-2326: No correlation between anti-drug antibodies and pharmacokinetics, efficacy or safety of Anakinra (Kineret(®)) in patients with severe CAPS
por: Wikén, M, et al.
Publicado: (2013)

Dada : Zurich, Berlin, Hannover, Cologne, New York, Paris /
por: Dickerman, Leah, 1964-
Publicado: (2005)

Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined genetic cause
por: Harrison, S, et al.
Publicado: (2015)

Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
por: Martínez-Pérez, Rosalía, et al.
Publicado: (2011)

Anakinra for systemic onset juvenile idiopathic arthritis: experience as a second versus first line treatment
por: Ricart, S, et al.
Publicado: (2011)

The phagocyte specific protein S100A12 as a novel biomarker in Muckle-Wells-Syndrome before and during therapy with Anakinra and Canakinumab (ACZ885)
por: Wittkowski, H, et al.
Publicado: (2008)

The IL-1 receptor antagonist anakinra (kineret®) stabilizes the NLRP3 mutation-specific risk for hearing loss in patients with severe cryopyrin-associated periodic syndromes (CAPS)
por: Leinonen, Mika, et al.
Publicado: (2014)

P01-020 – Starting time of inflammatory attacks in patients
por: Berktaş, F, et al.
Publicado: (2013)

CECR1 p.Gly47Arg mutations are not increased in frequency in Turkish Behçet's disease patients compared with healthy controls
por: Erer, B, et al.
Publicado: (2015)

Adalimumab and severe uveitis in juvenile idiopathic arthritis (JIA) therapy
por: Alpigiani, MG, et al.
Publicado: (2008)

Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
por: Joos, R, et al.
Publicado: (2011)

Quality of life in patients with juvenile arthritis: adalimumab might make a difference
por: Denisova, Rina, et al.
Publicado: (2011)

Administration of adalimumab in paediatric patients with juvenile idiopathic arthritis in South Ural region
por: Glazyrina, Galina
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2u836u39kt7u9t0rfj2bflpm2r